Covid-19 roundup: EMA starts rolling review of AstraZeneca vaccine; Novavax execs sell millions in stock ahead of PhIII
Though studies for the Covid-19 vaccine being developed by AstraZeneca and Oxford University researchers remain on hold in the US, Europe is speeding up its review.
The EMA announced Thursday that it is initiating the first rolling review of the vaccine candidate, a move that would accelerate the future approval process. By doing so, the agency’s human medicines committee has started evaluating the first batch of data, though it noted that much of the evidence has yet to be submitted.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.